# US 2019/0167715 A1 · Compositions and methods for treating and preventing proteinuria and endothelial erosion

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167715 A1
- Document ID: US20190167715A1
- Status: Published application
- Kind: A1
- Application number: 16/173,475
- Filed: 2018-10-29
- Published: 2019-06-06
- Earliest claimed: 2017-10-27
- Assignees: Zeta Biolongevity, Inc
- Applicants: Zeta Biolongevity, Inc.
- Inventors: Randal C. Thompson
- Web page: https://patentgrep.com/patent/US20190167715A1

## CPC

- A61K 33/14: Alkali metal chlorides; Alkaline earth metal chlorides
- A61K 31/10: Sulfides; Sulfoxides; Sulfones
- A61K 31/194: having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/355: Tocopherols, e.g. vitamin E
- A61K 31/7008: Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
- A61K 31/728: Hyaluronic acid
- A61K 31/737: Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate (A61K31/727 takes precedence)
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 36/63: Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K 38/40: Transferrins, e.g. lactoferrins, ovotransferrins
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 13/12: of the kidneys
- C12Y 304/21062: Subtilisin (3.4.21.62)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Y: ENZYMES

## Abstract

In some embodiments, a system and/or method may inhibit and/or ameliorate proteinuria and related comorbidities in a subject. In some embodiments, proteinuria and/or Endothelial Erosion (EE) and related comorbidities may be inhibited and/or ameliorated by maximizing a subject's serum zeta potential. A subject's serum zeta potential may be maximized by administering pharmaceutical compositions which: optimize the negative electrical surface charges of a subject's blood cells, plasma proteins, and/or endothelial surface layer; optimize the composition of a subject's bloodstream (e.g., ionic strength and ion concentrations), and/or optimize the properties of the subject's bloodstream (e.g., serum pH). In some embodiments, Proteinuria and/or EE and related comorbidities may be inhibited and/or ameliorated by: maximizing a subject's serum zeta potential; repairing damage to the endothelial surface layer in a subject; making up for a subject's urinary losses of plasma proteins; and/or optimizing blood flow and facilitating healing of damage caused by Proteinuria and/or EE.

## Claims

### Claim 1

A method of treating proteinuria, comprising:
adjusting a subject's serum zeta potential;
increasing the health of a subject's endothelial surface layer;
replenishing a subject's urinary losses of plasma proteins; and
ameliorating damage to a subject's glomerulus.

### Claim 2 (depends on 1)

The method of claim 1, wherein the subject's serum zeta potential is a potential for a subject's blood cells, plasma proteins, and endothelial surface layer to electrostatically repel one another.

### Claim 3 (depends on 1)

The method of claim 1, wherein adjusting a subject's serum zeta potential comprises increasing the subject's serum zeta potential.

### Claim 4 (depends on 1)

The method of claim 1, wherein adjusting a subject's serum zeta potential comprises maximizing the subject's serum zeta potential.

### Claim 5 (depends on 1)

The method of claim 1, wherein adjusting a subject's serum zeta potential comprises electrostatically inhibiting coagulation in the subject's blood serum.

### Claim 6 (depends on 1)

The method of claim 1, wherein adjusting a subject's serum zeta potential comprises administering a composition to the subject comprising sodium chloride, potassium chloride, magnesium chloride, potassium citrate, and/or olive leaf extract.

### Claim 7 (depends on 1)

The method of claim 1, wherein adjusting a subject's serum zeta potential comprises adjusting a pH of the subject's serum.

### Claim 8 (depends on 1)

The method of claim 1, wherein adjusting a subject's serum zeta potential comprises adjusting a pH of the subject's serum to between about 7.35 and about 7.45.

### Claim 9 (depends on 1)

The method of claim 1, wherein increasing the health of subject's endothelial surface layer comprises ameliorating damage to the endothelial surface layer.

### Claim 10 (depends on 1)

The method of claim 1, wherein increasing a health of subject's endothelial surface layer comprises administering a composition to the subject which comprises compounds used by the subject's own endothelial cells to form the subject's endothelial glycocalyx.

### Claim 11 (depends on 1)

The method of claim 1, wherein increasing the health of a subject's endothelial surface layer comprises administering a composition to the subject which comprises hyaluronic acid, N-acetyl glucosamine, glucosamine sulfate, chondroitin sulfate, n-acetyl cysteine, and/or methyl sulfonylmethane.

### Claim 12 (depends on 1)

The method of claim 1, wherein replenishing urinary losses of plasma proteins of the subject comprises administering a composition to the subject which comprises lactoferrin and sources of sodium, chloride, potassium, and magnesium.

### Claim 13 (depends on 1)

The method of claim 1, wherein ameliorating damage to a subject's glomerulus comprises administering a composition to the subject which comprises tocotrienols, nattokinase, n-acetyl cysteine, and methylsulfonylmethane.

### Claim 14 (depends on 13)

The method of claim 13, wherein tocotrienols comprise delta and gamma tocotrienols.

### Claim 15 (depends on 13)

The method of claim 13, wherein tocotrienols comprise delta and gamma tocotrienols in a 90:10 ratio respectively.

### Claim 16 (depends on 1)

The method of claim 1, wherein damage to a subject's glomerulus comprises scarring and/or sclerosis.

### Claim 17

A chemical composition for treating proteinuria, comprising:
a first group of compounds providing bioavailable sources of sodium, potassium, chloride, olive leaf extract, potassium citrate, and/or magnesium to adjust a subject's serum zeta potential;
a second group of compounds comprising hyaluronic acid, n-acetyl glucosamine, n-acetyl cysteine, methylsulfonylmethane, glucosamine sulfate and/or chondroitin sulfate to increase the health of a subject's endothelial surface layer;
a third group of compounds comprising bioavailable sources of magnesium, sodium, potassium, chloride, and/or lactoferrin to replenish a subject's urinary losses of plasma proteins; and
a fourth group of compounds comprising nattokinase, methylsulfonylmethane, n-acetyl cysteine and/or tocotrienols to ameliorate damage to a subject's glomerulus.

### Claim 18 (depends on 17)

The chemical composition of claim 17, wherein the first group of compounds provides bioavailable sources of sodium, potassium, chloride, olive leaf extract, potassium citrate, and magnesium.

### Claim 19 (depends on 17)

The chemical composition of claim 17, wherein the second group of compounds comprises hyaluronic acid, n-acetyl glucosamine, n-acetyl cysteine, methylsulfonylmethane, glucosamine sulfate and chondroitin sulfate.

### Claim 20 (depends on 17)

The chemical composition of claim 17, wherein the third group of compounds comprises bioavailable sources of magnesium, sodium, potassium, chloride, and lactoferrin.

### Claim 21 (depends on 17)

The chemical composition of claim 17, wherein the fourth group comprises nattokinase, methylsulfonylmethane, n-acetyl cysteine, and tocotrienols.

### Claim at position 22

-30. (canceled)
